Scynexis (SCYX) Shares Outstanding (2013 - 2026)
Scynexis' (SCYX) quarterly Shares Outstanding (Entity) came in at $6.4 million in Q1 2026, up 3.08% YoY from $6.2 million in Q1 2025, and up 17.03% on a QoQ basis from $5.4 million in Q4 2025.
Scynexis (SCYX) Shares Outstanding (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 14 years of Shares Outstanding (Entity) data on file, last reported at $6.4 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 3.08% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (up 3.08% YoY) and the FY2025 annual result came in at $5.4 million, down 10.25% from the prior year.
- Shares Outstanding (Entity) climbed to $6.4 million in Q1 2026, from $5.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $6.4 million in Q1 2026 to a low of $3.7 million in Q1 2022.
- A 5-year average of $5.8 million and a median of $6.0 million in 2023 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) jumped 98.88% — and 2025, when it dropped 13.7%.
- Tracing SCYX's Shares Outstanding (Entity) over 5 years: stood at $5.3 million in 2022, then grew by 12.29% to $6.0 million in 2023, then climbed by 1.38% to $6.1 million in 2024, then retreated by 10.25% to $5.4 million in 2025, then grew by 17.03% to $6.4 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $6.4 million (Q1 2026), $5.4 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | 832.44 Mn |
| 10 | Scynexis | 61.90 Mn | -52.80 Mn | - | 11.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.82 Mn |
| Mar 31, 2026 | 6.37 Mn |
| Dec 31, 2025 | 6.24 Mn |
| Sep 30, 2025 | 6.24 Mn |
| Jun 30, 2025 | 6.22 Mn |
| Mar 31, 2025 | 6.18 Mn |
| Dec 31, 2024 | 6.06 Mn |
| Sep 30, 2024 | 6.08 Mn |
| Jun 30, 2024 | 6.06 Mn |
| Mar 31, 2024 | 6.03 Mn |
| Dec 31, 2023 | 5.98 Mn |
| Sep 30, 2023 | 5.99 Mn |
| Jun 30, 2023 | 5.98 Mn |
| Mar 31, 2023 | 5.97 Mn |
| Dec 31, 2022 | 5.33 Mn |
| Sep 30, 2022 | 5.94 Mn |
| Jun 30, 2022 | 5.41 Mn |
| Mar 31, 2022 | 4.01 Mn |
| Dec 31, 2021 | 3.30 Mn |
| Sep 30, 2021 | 3.33 Mn |